Arrowhead Pharmaceuticals (ARWR) Competitors $20.51 +1.73 (+9.21%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$20.58 +0.06 (+0.32%) As of 08/15/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, and RNAShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences BridgeBio Pharma (NASDAQ:BBIO) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Does the media prefer BBIO or ARWR? In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than BridgeBio Pharma. MarketBeat recorded 36 mentions for Arrowhead Pharmaceuticals and 19 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.68 beat Arrowhead Pharmaceuticals' score of 0.66 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, BBIO or ARWR? BridgeBio Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Do insiders and institutionals believe in BBIO or ARWR? 99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer BBIO or ARWR? BridgeBio Pharma currently has a consensus target price of $61.35, indicating a potential upside of 19.55%. Arrowhead Pharmaceuticals has a consensus target price of $43.14, indicating a potential upside of 110.35%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better valuation and earnings, BBIO or ARWR? BridgeBio Pharma has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M44.21-$535.76M-$4.09-12.55Arrowhead Pharmaceuticals$3.55M798.79-$599.49M-$1.28-16.02 Is BBIO or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% Arrowhead Pharmaceuticals N/A -40.91%-11.62% SummaryBridgeBio Pharma beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84B$3.14B$5.73B$9.79BDividend YieldN/A2.21%3.90%4.13%P/E Ratio-16.0220.7631.0725.05Price / Sales798.79369.14444.16106.06Price / CashN/A41.5625.2228.44Price / Book13.329.649.255.96Net Income-$599.49M-$54.74M$3.26B$265.21M7 Day Performance24.91%6.56%7.39%4.22%1 Month Performance8.81%4.82%4.22%0.77%1 Year Performance-9.65%15.81%30.30%24.69% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.1945 of 5 stars$20.51+9.2%$43.14+110.4%-9.6%$2.84B$3.55M-16.02400Trending NewsInsider TradeAnalyst RevisionGap UpHigh Trading VolumeBBIOBridgeBio Pharma4.359 of 5 stars$48.24+3.6%$61.35+27.2%+110.3%$9.22B$221.90M-11.79400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.3705 of 5 stars$105.240.0%$109.00+3.6%+282.9%$8.96B$42.28M-106.3030Positive NewsShort Interest ↓ELANElanco Animal Health2.9071 of 5 stars$17.10+2.6%$17.33+1.3%+24.1%$8.50B$4.44B19.899,000News CoverageBPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.9883 of 5 stars$11.17-2.8%$16.50+47.7%+5.9%$7.59B$29.05M-44.68860News CoverageGap DownGRFSGrifols3.6884 of 5 stars$10.60-0.6%$10.30-2.8%+51.8%$7.29B$7.81B9.0623,822Positive NewsEx-DividendShort Interest ↑LEGNLegend Biotech3.7348 of 5 stars$36.24-2.1%$73.33+102.4%-34.1%$6.66B$728.30M-61.422,609News CoverageEarnings ReportAnalyst ForecastRVMDRevolution Medicines4.164 of 5 stars$34.70-0.9%$68.82+98.3%-15.2%$6.49B$11.58M-7.71250News CoverageAnalyst ForecastGap UpRYTMRhythm Pharmaceuticals3.7419 of 5 stars$94.31+2.5%$101.57+7.7%+111.8%$6.26B$130.13M-31.33140News CoverageInsider TradeRNAAvidity Biosciences3.1828 of 5 stars$45.75-1.2%$67.00+46.4%+3.3%$5.51B$8.93M-15.25190Positive NewsInsider Trade Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access